Abstract
Bone metastasis of a malignant tumor causes various skeletal related events (SREs) and often harms patients' QOL. Bisphosphonates is a standard treatment medicine for the patient with bone metastasis of a malignant tumor. It is possible that Bisphosphonates improve and also maintain their QOL because it restrains manifestation of SREs. Particularly zoledronic acid is recommended for bone metastasis of all malignant tumors in a guideline of American Society of Clinical Oncology (ASCO). Bisphosphonates should be used positively for profit of the patient.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
